Study guide

12.2 Prospective Drug Utilization Review

Connecticut Multistate Pharmacy Jurisprudence Examination CT MPJE

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the Connecticut MPJE 1.2 Application, Fees, ATT, and Pearson VUE 1.3 Blueprint, Scoring, Retakes, and Study Strategy

2 Connecticut Regulatory Structure

2.1 DCP and the Commission of Pharmacy 2.2 Chapter 400j, 420b/420c, and RCSA 20-576 2.3 Federal vs Connecticut Law (More Restrictive Rule)

3 Pharmacist Licensure, Interns, PIC, and CE

3.1 Pharmacist Qualifications and Exam Path 3.2 Interns, Score Transfer, and Reciprocity 3.3 Pharmacist-in-Charge / Pharmacist Manager 3.4 License Renewal and Continuing Education

4 Technicians and Non-Pharmacist Personnel

4.1 Technician Registration and Certification 4.2 Community Technician Ratios (20-576-36) 4.3 Institutional Ratios and Advanced Pharmacy Technicians 4.4 Technician Limitations, Interns, and Unlicensed Staff

5 Discipline, Impairment, and Unlicensed Practice

5.1 Disciplinary Grounds (CGS § 20-579) 5.2 Impaired Practitioner Reporting and Programs 5.3 Unlicensed Practice, Penalties, and Appeals

6 Federal Drug Law Foundations

6.1 FDCA, Adulteration, and Misbranding 6.2 FDA Approval, Recalls, and OTC vs Rx 6.3 DSCSA, HIPAA, OBRA ’90, and PPPA

7 Federal Controlled Substances

7.1 CSA Schedules and Definitions 7.2 DEA Registration and Forms 222, 106, 41 7.3 Federal Controlled-Substance Prescription Rules 7.4 Inventory, Theft, Loss, and Disposal

8 Prescription Issuance in Connecticut

8.1 Who May Prescribe in Connecticut 8.2 Noncontrolled Prescription Form and Content 8.3 Controlled Prescriptions and the EPCS Mandate

9 Refills, Partial Fills, and Opioid Limits

9.1 Refill Authority (Noncontrolled and CIII–V) 9.2 Partial Fills of Schedule II Prescriptions 9.3 Connecticut Opioid Supply Limits (7-day / 5-day)

10 Administration, CDTM, and Standing Orders

10.1 Pharmacist Immunization Authority 10.2 Collaborative Drug Therapy Management 10.3 Naloxone and Opioid Antagonist Access 10.4 Emergency and Hormonal Contraception

11 Counseling, Confidentiality, and Returns

11.1 Counseling and Offer to Counsel 11.2 HIPAA and Connecticut Confidentiality 11.3 Return, Reuse, and Take-Back

12 Corresponding Responsibility and DUR

12.1 Corresponding Responsibility and Legitimate Medical Purpose 12.2 Prospective Drug Utilization Review 12.3 Exceptions and Conditions Prohibiting Dispensing

13 Transfers, Labeling, Packaging, and Delivery

13.1 Transferring Prescriptions 13.2 Labeling of Dispensed Drugs 13.3 Packaging and the Poison Prevention Packaging Act 13.4 Delivery of Drugs

14 CPMRS, Substitution, and Nonprescription Drugs

14.1 CPMRS Query and Reporting 14.2 Generic and Biosimilar Substitution 14.3 CMEA and Behind-the-Counter Products 14.4 OTC Labeling, Hazardous, and Restricted Nonprescription Drugs

15 Ordering, Records, and Inventories

15.1 Ordering and Acquisition (DEA 222/CSOS) 15.2 Distribution and DSCSA Records 15.3 Recordkeeping Content and Three-Year Retention 15.4 Controlled-Substance Inventories and CT Perpetual CII

16 Storage, Security, and Hazardous Drugs

16.1 Controlled-Substance Storage and Security 16.2 Hazardous Drugs (USP <800>, NIOSH) 16.3 Non-Pharmacist Access to Drugs

17 Compounding and Central Fill

17.1 Nonsterile Compounding (USP <795>, RCSA 20-576-69) 17.2 Sterile Compounding (USP <797>, RCSA 20-576-64) 17.3 Central Fill, 503A, and 503B Outsourcing

18 Pharmacy Permits and Practice Settings

18.1 Pharmacy License, Hours, Manager, and Signage 18.2 Nonresident, Hospital, Nuclear, and Automated Dispensing 18.3 Inspection, Closure, and Facility Discipline

12.2 Prospective Drug Utilization Review

Key Takeaways Explain This Topic AI

OBRA ’90 (42 U.S.C. § 1396r-8(g)) requires prospective DUR before a Medicaid outpatient fill: therapeutic duplication, drug–disease contraindication, drug–drug interaction, incorrect dose or duration, drug–allergy, and clinical abuse or misuse.

CGS § 20-620 implements that duty for Connecticut Medicaid recipients: before or simultaneously with dispensing, the pharmacist reviews drugs the pharmacy dispensed to that person in the previous 180 days and screens for those same problems plus other significant clinical issues.

CGS § 20-614 extends the offer to counsel beyond Medicaid (Chapter 11). Statutory prospective-DUR text in § 20-620 is Medicaid-specific; ignoring a serious interaction on a cash patient is still negligent practice and can be a corresponding-responsibility problem on a controlled substance.

CGS § 20-635 and RCSA §§ 20-635-1 to 20-635-6 require every pharmacy to keep a written quality-assurance program that detects, identifies, and prevents prescription errors. A prescription error is an act or omission of clinical significance relating to dispensing.

RCSA § 20-635-3 requires immediate notice to the patient and prescriber of a discovered error; RCSA § 20-635-4 requires a QA review no later than two business days. The statute does not require the pharmacy to file every harm event with DCP; consumers may report using the posted Drug Control number, and QA records must be produced within 48 hours if DCP is investigating.

Last updated: August 2026

Why prospective DUR is not optional software

Quick Answer: OBRA ’90 ( 42 U.S.C. § 1396r-8(g) ) requires prospective drug utilization review (DUR) before a Medicaid outpatient fill. CGS § 20-620 implements it in Connecticut: review drugs this pharmacy dispensed to that recipient in the previous 180 days , and screen for therapeutic duplication , drug–disease contraindication, drug–drug interaction, incorrect dose or duration , drug–allergy , clinical abuse or misuse , and other significant clinical issues. CGS § 20-635 is the quality-assurance overlay: a written program to detect, identify, and prevent prescription errors , with immediate patient-and-prescriber notice and a review starting no later than two business days . Counseling’s offer-to-discuss rule is CGS § 20-614 ( Chapter 11 ).

NABP Competency 3.3 (DUR) and the public-health/QA slice of 2.5.1 sit together because a missed interaction is both a clinical screen failure and, if it reaches the patient, a prescription error under § 20-635 . Candidates lose items by treating DUR as “whatever the claims switch hard-stop said,” by assuming cash patients have no review duty of any kind, or by inventing a statute that makes the pharmacy file every error with DCP . Open the federal floor, then the Connecticut Medicaid statute, then the QA regulations.

OBRA ’90 — the federal Medicaid floor

Section 4401 of the Omnibus Budget Reconciliation Act of 1990 required each state, as a condition of Medicaid funding, to run a drug-use review program. The pharmacist-facing pieces are:

  • A patient record that makes review possible
  • Prospective DUR before dispensing
  • An offer to counsel the Medicaid patient or caregiver
  • A state retrospective DUR board (not a bench task)

The prospective screens in 42 U.S.C. § 1396r-8(g) and 42 CFR Part 456, Subpart K are the list the exam quotes: therapeutic duplication , drug–disease contraindication, drug–drug interaction, incorrect dosage or duration , drug–allergy interactions, and clinical abuse or misuse . Over- and under-utilization show up as dose, duration, and abuse/misuse problems. Appropriateness is the point of the whole screen, not a seventh unlabeled statute.

OBRA is a Medicaid floor . It is not a statement that cash-pay patients may swallow unreviewed warfarin. Connecticut’s statutory prospective-DUR sentence is § 20-620 and is written for individuals eligible under the listed Medicaid sections. CGS § 20-614 already extends the offer to counsel to patients generally ( Chapter 11 ). Corresponding responsibility ( section 12.1 ) and § 20-579(a)(16) negligent work still attach if a pharmacist releases a documented, lethal interaction to a cash patient because “OBRA is Medicaid-only.” Teach the citation correctly: quote § 20-620 on a Medicaid-statute item; do not invent a second DUR statute that Chapter 400j has not published for cash patients.

CGS § 20-620 — 180 days in this pharmacy

CGS § 20-620 is Connecticut’s OBRA implementation for Medicaid recipients . Before or simultaneously with dispensing, the pharmacist must:

  • Obtain, record, and maintain pertinent patient information about the recipient
  • Review drugs previously dispensed to that individual by that pharmacy during the previous 180 days

Screen for potential drug-therapy problems due to therapeutic duplication , a contraindication between a drug and a disease , the interaction of one drug with another , incorrect drug dosage or duration , the interaction of a drug and an allergy , clinical abuse or misuse , and any other significant clinical issues relating to appropriate use

Offer , whenever practicable, to discuss the drugs and counsel on correct usage (in person, with a written-offer exception when the person at the counter is not the patient or the pharmacist determines a written offer is appropriate)

The 180-day lookback is this pharmacy’s fills, not a promise that the statute downloaded every other store’s profile. That is why CPMRS still matters for controlled substances and why a new-to-store Medicaid patient can have a thin local profile. The screen is still mandatory.

Screen (OBRA ’90 / CGS § 20-620) Connecticut counter example Not the screen

Therapeutic duplication Two long-acting opioids, or two ACE inhibitors from different prescribers Two strengths of the same inhaler that the prescriber stacked on purpose

Drug–disease contraindication NSAID for a patient whose profile lists decompensated heart failure An allergy the profile does not contain and the patient denies

Drug–drug interaction Warfarin + metronidazole; opioid + benzodiazepine + carisoprodol Two topical creams with no systemic interaction

Incorrect dose or duration (over/under-utilization) Methotrexate daily instead of weekly; a 30-day first opioid that blows § 20-14o A medically justified oncology dose that looks “high” to a casual glance

Drug–allergy Amoxicillin with a documented anaphylaxis to penicillin A family member’s allergy written on the wrong profile

Clinical abuse or misuse Early CII fills, cocktail regimens, multi-pharmacy hopping A single late statin refill

Software alerts are a tool. § 20-620 assigns the review to a pharmacist . A technician clicking “override – doctor aware” on every warfarin alert is not prospective DUR. The pharmacist who never looks at the queue is not reviewing.

CGS § 20-635 — quality assurance, not an auto-report to DCP

CGS § 20-635 is captioned prescription error reporting . Read it as three duties, not one.

Definition. A prescription error is an act or omission of clinical significance relating to the dispensing of a drug . Wrong drug, wrong strength, wrong patient, missed contraindication that reached the patient, and a quantity so wrong it is clinically significant all fit. A purely clerical bag-sticker miss that never affected the drug may or may not be “of clinical significance”—when in doubt, treat it as an error and review it.

Consumer-facing reporting. The pharmacy must display an informational statement, in lettering readable at the prescription counter, telling patients they may contact DCP Drug Control if they think an error occurred. UConn’s published signage checklist quotes the required idea: “If you have a concern that an error may have occurred in the dispensing of your prescription you may contact the Department of Consumer Protection, Drug Control Division, by calling 1-800-842-2649.” That is how the public reports . It is not a statute that says the pharmacy must itself file every harm event with DCP.

Internal QA program. § 20-635(d) directs the Commissioner, with the Commission’s advice, to require each pharmacy to implement a written quality-assurance program designed to detect, identify, and prevent prescription errors. The policies must include how to communicate the error to the prescribing practitioner and to the patient (or caregiver or appropriate family member if the patient is deceased or cannot comprehend), including methods of correcting the error or reducing its negative impact . Records of reported errors must be kept ready for inspection for at least three years and produced to the Commissioner within 48 hours when DCP is investigating a report of a prescription error.

RCSA §§ 20-635-1 through 20-635-6 fill in the operations:

20-635-2 — implement the program; document and assess errors to find cause and an appropriate system response; use findings to change workflow

20-635-3 — unless the prescriber or patient already informed the pharmacy, a pharmacist who discovers or is told of an error shall immediately notify the patient and the prescribing practitioner, and shall communicate how to correct it and reduce harm

20-635-4 — a quality-assurance review for each error starts as soon as reasonably possible, no later than two business days from discovery, and the record names reviewers, facts, patient/prescriber contact, findings, and recommended system changes

20-635-5 — keep a written copy of the program on the premises ; keep review records three years , filed by date, producible within 48 hours even if stored off-site

20-635-6 — give each pharmacist a copy of the program; tell all pharmacy personnel to relay a discovered error immediately to a pharmacist on duty ; tell staff about system changes that came out of reviews

§ 20-635(e) then protects the QA file: those records need not be disclosed under FOIA (CGS § 1-210(a)) for six months after creation, and they shall not be subject to subpoena or discovery or introduced into evidence in a judicial proceeding except as otherwise specifically provided by law . The QA program is for prevention , not for a plaintiff’s fishing expedition. It is still available to DCP on the 48-hour clock when Drug Control is investigating.

What the statute does not require. Open 20-635 and the six regulations: there is no sentence that says “the pharmacy shall report every harm event to DCP within X hours.” Consumers may call the posted number. DCP may then investigate and demand the QA record. Inventing a 24-hour mandatory board report because another state has one is a wrong answer on the Connecticut MPJE.

Scenario: two alerts, one missed error

A Medicaid patient in Stamford is due for warfarin. The profile, looking back 180 days in this pharmacy , already lists metronidazole from last week and a documented penicillin anaphylaxis. The claims switch fires a warfarin interaction. The pharmacist who documents the INR plan with the prescriber and does not release metronidazole blindly has done § 20-620 prospective DUR. The same afternoon a technician dispenses the penicillin-allergic patient’s amoxicillin. That release is a prescription error . RCSA § 20-635-3 requires immediate notice to the patient and the prescriber, with instructions to stop the amoxicillin and reduce harm. The QA review must start within two business days . Posting the Drug Control number does not replace that notice, and failing to call DCP the same night is not itself a § 20-635 violation—failing to notify the patient, failing to review, and leaving recalled or wrong-drug stock in the bay are.

CT may be stricter; more-restrictive wins.

Official anchors

42 U.S.C. § 1396r-8(g) — OBRA ’90 prospective DUR.

CGS § 20-620 — Medicaid 180-day review and listed screens.

CGS § 20-635 — prescription-error definition, QA program, three-year records, 48-hour DCP production, six-month FOIA delay.

RCSA §§ 20-635-1 to 20-635-6 — immediate notice, two-business-day review, on-site program copy, staff relay duty.